NCT00317109View on ClinicalTrials.gov

Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

April 19, 2006

Primary Completion Date

May 1, 2007

Study Completion Date

May 17, 2007

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Tritanrix™- HepB

One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months

BIOLOGICAL

Hiberix™

One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months

BIOLOGICAL

Mencevax™ ACW

One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months

Trial Locations (3)

0250

GSK Investigational Site, Brits

0208

GSK Investigational Site, Ga-Rankuwa

0145

GSK Investigational Site, Rooihuiskraal

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY